Harbour JW - Search Results

1

BAP1 regulates epigenetic switch from pluripotency to differentiation in developmental lineages giving rise to BAP1-mutant cancers.

Kuznetsov JN, Aguero TH, Owens DA, Kurtenbach S, Field MG, Durante MA, Rodriguez DA, King ML, Harbour JW. Kuznetsov JN, et al. Among authors: harbour jw. Sci Adv. 2019 Sep 18;5(9):eaax1738. doi: 10.1126/sciadv.aax1738. eCollection 2019 Sep. Sci Adv. 2019. PMID: 31555735 Free PMC article.

2

Genomic, prognostic, and cell-signaling advances in uveal melanoma.

Harbour JW. Harbour JW. Am Soc Clin Oncol Educ Book. 2013:388-91. doi: 10.14694/EdBook_AM.2013.33.388. Am Soc Clin Oncol Educ Book. 2013. PMID: 23714557 Free PMC article. Review.

3

Recent developments in prognostic and predictive testing in uveal melanoma.

Field MG, Harbour JW. Field MG, et al. Among authors: harbour jw. Curr Opin Ophthalmol. 2014 May;25(3):234-9. doi: 10.1097/ICU.0000000000000051. Curr Opin Ophthalmol. 2014. PMID: 24713608 Free PMC article. Review.

4

GNAQ/11 mutations in uveal melanoma: is YAP the key to targeted therapy?

Field MG, Harbour JW. Field MG, et al. Among authors: harbour jw. Cancer Cell. 2014 Jun 16;25(6):714-5. doi: 10.1016/j.ccr.2014.05.028. Cancer Cell. 2014. PMID: 24937456 Free PMC article.

5

Prognostic parameters in uveal melanoma and their association with BAP1 expression.

van Essen TH, van Pelt SI, Versluis M, Bronkhorst IH, van Duinen SG, Marinkovic M, Kroes WG, Ruivenkamp CA, Shukla S, de Klein A, Kiliç E, Harbour JW, Luyten GP, van der Velden PA, Verdijk RM, Jager MJ. van Essen TH, et al. Among authors: harbour jw. Br J Ophthalmol. 2014 Dec;98(12):1738-43. doi: 10.1136/bjophthalmol-2014-305047. Epub 2014 Aug 21. Br J Ophthalmol. 2014. PMID: 25147369 Free PMC article.

6

Skewed expression of the genes encoding epigenetic modifiers in high-risk uveal melanoma.

Herlihy N, Dogrusöz M, van Essen TH, Harbour JW, van der Velden PA, van Eggermond MC, Haasnoot GW, van den Elsen PJ, Jager MJ. Herlihy N, et al. Among authors: harbour jw. Invest Ophthalmol Vis Sci. 2015 Jan 15;56(3):1447-58. doi: 10.1167/iovs.14-15250. Invest Ophthalmol Vis Sci. 2015. PMID: 25593028 Free PMC article.

7

PRAME as an Independent Biomarker for Metastasis in Uveal Melanoma.

Field MG, Decatur CL, Kurtenbach S, Gezgin G, van der Velden PA, Jager MJ, Kozak KN, Harbour JW. Field MG, et al. Among authors: harbour jw. Clin Cancer Res. 2016 Mar 1;22(5):1234-42. doi: 10.1158/1078-0432.CCR-15-2071. Clin Cancer Res. 2016. PMID: 26933176 Free PMC article.

8

Driver Mutations in Uveal Melanoma: Associations With Gene Expression Profile and Patient Outcomes.

Decatur CL, Ong E, Garg N, Anbunathan H, Bowcock AM, Field MG, Harbour JW. Decatur CL, et al. Among authors: harbour jw. JAMA Ophthalmol. 2016 Jul 1;134(7):728-33. doi: 10.1001/jamaophthalmol.2016.0903. JAMA Ophthalmol. 2016. PMID: 27123562 Free PMC article.

9

Epigenetic reprogramming and aberrant expression of PRAME are associated with increased metastatic risk in Class 1 and Class 2 uveal melanomas.

Field MG, Durante MA, Decatur CL, Tarlan B, Oelschlager KM, Stone JF, Kuznetsov J, Bowcock AM, Kurtenbach S, Harbour JW. Field MG, et al. Among authors: harbour jw. Oncotarget. 2016 Sep 13;7(37):59209-59219. doi: 10.18632/oncotarget.10962. Oncotarget. 2016. PMID: 27486988 Free PMC article.

10

PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma.

Gezgin G, Luk SJ, Cao J, Dogrusöz M, van der Steen DM, Hagedoorn RS, Krijgsman D, van der Velden PA, Field MG, Luyten GPM, Szuhai K, Harbour JW, Jordanova ES, Heemskerk MHM, Jager MJ. Gezgin G, et al. Among authors: harbour jw. JAMA Ophthalmol. 2017 Jun 1;135(6):541-549. doi: 10.1001/jamaophthalmol.2017.0729. JAMA Ophthalmol. 2017. PMID: 28448663 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

230 results

Search Page